PetMed Express, Inc. (PETS)
NASDAQ: PETS · Real-Time Price · USD
1.740
-0.020 (-1.14%)
At close: Dec 4, 2025, 4:00 PM EST
1.750
+0.010 (0.57%)
After-hours: Dec 4, 2025, 6:25 PM EST
PetMed Express Revenue
In the fiscal year ending March 31, 2025, PetMed Express had annual revenue of $226.97M, down -17.19%. PetMed Express had revenue of $46.47M in the quarter ending March 31, 2025, a decrease of -21.95%.
Revenue (ttm)
$226.97M
Revenue Growth
-17.19%
P/S Ratio
0.16
Revenue / Employee
$1,311,977
Employees
173
Market Cap
36.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 226.97M | -47.12M | -17.19% |
| Mar 31, 2024 | 274.10M | 26.53M | 10.71% |
| Mar 31, 2023 | 247.57M | -24.71M | -9.08% |
| Mar 31, 2022 | 272.28M | -31.30M | -10.31% |
| Mar 31, 2021 | 303.58M | 19.46M | 6.85% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PETS News
- 8 days ago - PetMeds Extends Existing Shareholder Rights Plan - GlobeNewsWire
- 8 days ago - Pets At Home's Shares Purr As Retailer Avoids Fresh Profit Warning - Forbes
- 21 days ago - PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq - GlobeNewsWire
- 4 weeks ago - PETMED EXPRESS INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds PetMed Express Investors of the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 6 weeks ago - PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair - GlobeNewsWire
- 7 weeks ago - PETMED REMINDER: Bragar Eagel & Squire, P.C. Reminds PetMed Express Investors of the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 7 weeks ago - PetMeds® Files Form 10-K for Fiscal 2025 - GlobeNewsWire
- 7 weeks ago - PetMed Express (PETS) Faces Investor Scrutiny Amid Filing Delays, Executive Departures, Admitted Accounting Rule Violations -- Hagens Berman - GlobeNewsWire